Back to search
FDAFDA · Food and drugs·Recall number D-1659-2019

FENTANYL 2MCG/ML BUPIVACAINE 0.125% IN NACL 0.9% SRY C-II, 50ML per syringe (C-II) RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0207-89

Published August 14, 2019 · Recall initiated: June 19, 2019

Summary

FDA records drug Class II recall D-1659-2019, published August 14, 2019 and initiated June 19, 2019. Recalling firm: RXQ Compounding LLC; Status: Terminated; Reported quantity: N/A; Lot: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RXQ Compounding LLC
Distributor
Nationwide USA
Lot
All lots within expiry
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was FENTANYL 2MCG/ML BUPIVACAINE 0.125% IN NACL 0.9% SRY C-II, 50ML per syringe (C-II) RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0207-89 recalled?

Yes. FDA published recall D-1659-2019 on August 14, 2019. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Press Release